S&P 500 Healthcare stocks: today's ranking and data
The S&P 500 has 59 companies in Healthcare today. It accounts for 10.0% of the market value of the index companies. Its median P/E is 32.2, against 23.7 for the index as a whole.
What Healthcare is and what drives its earnings
What it includes. Drug makers and biotech, medical device and supply makers, health insurers and managed-care companies, drug distributors, hospitals and clinics, and diagnostics, lab and research-tools companies.
What drives its earnings. For drug makers, the patent cycle (when a drug's patent expires, generics arrive and its sales drop sharply), clinical trials and FDA approvals. Across the sector, drug pricing and what Medicare and Medicaid reimburse. For insurers, the gap between the premiums they collect and the medical costs they pay. And underneath it all, an aging population.
How it behaves. It is considered defensive because demand for health care depends little on the economic cycle, but it carries a risk of its own, regulatory and political: a change in drug pricing or public reimbursement hits many companies in the sector at once.
The classification is the one used by this site's data provider, similar to but not the same as GICS, S&P's standard: this sector roughly matches "Health Care". Counts may therefore differ from other sources.
All 59 stocks in the sector, by today's multi-factor rank
The rank is the order produced by a quantitative model on data as of Nov 3, 2026: the average of four factors (momentum, value, quality and growth) computed from public data, against the 461 index companies that score. It is a calculation, not a recommendation to buy or sell: it knows nothing about anyone's situation, horizon or risk, and the returns of portfolios built with it are simulated. How it is computed: see the methodology.
| In sector | Index rank | Company | P/E | Market cap |
|---|---|---|---|---|
| 1 | 29 of 461 | CVS CVS Health | 9.3 | $102.55B |
| 2 | 33 of 461 | LLY Eli Lilly | 46.4 | $1.27T |
| 3 | 34 of 461 | CNC Centene | 24.8 | $35.89B |
| 4 | 50 of 461 | ELV Elevance Health | 18.2 | $92.92B |
| 5 | 63 of 461 | SOLV Solventum | 11.0 | $15.31B |
| 6 | 72 of 461 | ABBV AbbVie | 49.7 | $510.38B |
| 7 | 76 of 461 | VTRS Viatris | — | $21.81B |
| 8 | 90 of 461 | HSIC Henry Schein | 24.2 | $9.74B |
| 9 | 98 of 461 | DXCM DexCom | 34.6 | $32.80B |
| 10 | 109 of 461 | CI Cigna | 12.5 | $80.09B |
| 11 | 122 of 461 | UHS Universal Health Services | 8.2 | $11.34B |
| 12 | 127 of 461 | HUM Humana | 39.3 | $49.89B |
| 13 | 133 of 461 | JNJ Johnson & Johnson | 41.3 | $655.29B |
| 14 | 145 of 461 | BMY Bristol-Myers Squibb | 13.9 | $128.59B |
| 15 | 146 of 461 | DGX Quest Diagnostics | 25.2 | $27.97B |
| 16 | 155 of 461 | CAH Cardinal Health | 35.6 | $59.65B |
| 17 | 156 of 461 | RVTY Revvity | 75.8 | $17.69B |
| 18 | 158 of 461 | MCK McKesson | 27.5 | $119.65B |
| 19 | 164 of 461 | WST West Pharmaceutical Services | 45.8 | $28.40B |
| 20 | 165 of 461 | AMGN Amgen | 27.4 | $255.35B |
| 21 | 167 of 461 | VRTX Vertex Pharmaceuticals | 34.9 | $137.42B |
| 22 | 184 of 461 | MRK Merck | 149.5 | $365.24B |
| 23 | 188 of 461 | COR Cencora | 26.0 | $66.80B |
| 24 | 189 of 461 | UNH UnitedHealth | 23.1 | $363.20B |
| 25 | 192 of 461 | REGN Regeneron Pharmaceuticals | 21.2 | $99.40B |
| 26 | 197 of 461 | WAT Waters | 193.8 | $45.48B |
| 27 | 204 of 461 | TECH Bio-Techne | 63.3 | $11.43B |
| 28 | 208 of 461 | BIIB Biogen | 107.5 | $36.86B |
| 29 | 221 of 461 | EW Edwards Lifesciences | 56.9 | $57.08B |
| 30 | 227 of 461 | LH Labcorp | 29.8 | $29.53B |
| 31 | 233 of 461 | IDXX IDEXX Laboratories | 47.2 | $55.22B |
| 32 | 236 of 461 | BAX Baxter International | — | $13.87B |
| 33 | 240 of 461 | BDX Becton, Dickinson | 62.4 | $56.40B |
| 34 | 250 of 461 | A Agilent Technologies | 34.8 | $49.76B |
| 35 | 260 of 461 | TMO Thermo Fisher Scientific | 37.0 | $259.60B |
| 36 | 267 of 461 | ZBH Zimmer Biomet | 27.0 | $21.26B |
| 37 | 270 of 461 | COO Cooper Companies | 22.0 | $12.21B |
| 38 | 274 of 461 | VEEV Veeva Systems | 50.3 | $49.75B |
| 39 | 278 of 461 | RMD ResMed | 21.8 | $33.69B |
| 40 | 295 of 461 | MDT Medtronic | 25.7 | $133.59B |
| 41 | 307 of 461 | PFE Pfizer | 43.6 | $173.79B |
| 42 | 310 of 461 | INCY Incyte | 64.2 | $24.61B |
| 43 | 321 of 461 | DHR Danaher | 38.0 | $163.36B |
| 44 | 326 of 461 | ALGN Align Technology | 23.7 | $11.57B |
| 45 | 357 of 461 | GEHC GE HealthCare Technologies | 18.2 | $39.05B |
| 46 | 366 of 461 | IQV IQVIA | 32.2 | $43.64B |
| 47 | 367 of 461 | ISRG Intuitive Surgical | 58.5 | $170.78B |
| 48 | 370 of 461 | STE STERIS | 30.1 | $24.00B |
| 49 | 383 of 461 | CRL Charles River Laboratories International | 341.4 | $15.95B |
| 50 | 402 of 461 | SYK Stryker | 35.6 | $127.16B |
| 51 | 404 of 461 | PODD Insulet | 30.4 | $11.26B |
| 52 | 430 of 461 | BSX Boston Scientific | 19.5 | $66.77B |
| 53 | 436 of 461 | ZTS Zoetis | 14.4 | $36.06B |
| 54 | 444 of 461 | ABT Abbott Laboratories | 42.6 | $198.24B |
| 55 | 446 of 461 | GILD Gilead Sciences | — | $215.03B |
| — | not scored today | DVA DaVita | 14.0 | $11.88B |
| — | not scored today | HCA HCA Healthcare | 16.8 | $105.73B |
| — | not scored today | MRNA Moderna | — | $99.12B |
| — | not scored today | MTD Mettler-Toledo International | 38.9 | $34.56B |
"—" under P/E: no positive P/E (negative trailing earnings or missing at the source). 4 stocks do not get a multi-factor score today because a factor is missing; they go last, alphabetically. The full S&P 500 ranking →
Healthcare P/E against the index
| Median P/E | Companies with a positive P/E | |
|---|---|---|
| Healthcare | 32.2 | 55 of 59 |
| S&P 500 | 23.7 | 474 of 500 |
The median is the company in the middle: a few firms with near-zero earnings and huge P/Es do not move it, which is what happens to the average. Loss-making companies have no P/E and are left out.
Guide: P/E ratio explained · all guides
The 10 largest in the sector by market cap
| # | Company | Market cap | Weight in sector | Rank today |
|---|---|---|---|---|
| 1 | LLY Eli Lilly | $1.27T | 18.2% | 33 |
| 2 | JNJ Johnson & Johnson | $655.29B | 9.4% | 133 |
| 3 | ABBV AbbVie | $510.38B | 7.3% | 72 |
| 4 | MRK Merck | $365.24B | 5.2% | 184 |
| 5 | UNH UnitedHealth | $363.20B | 5.2% | 189 |
| 6 | TMO Thermo Fisher Scientific | $259.60B | 3.7% | 260 |
| 7 | AMGN Amgen | $255.35B | 3.6% | 165 |
| 8 | GILD Gilead Sciences | $215.03B | 3.1% | 446 |
| 9 | ABT Abbott Laboratories | $198.24B | 2.8% | 444 |
| 10 | PFE Pfizer | $173.79B | 2.5% | 307 |
Total market value (price times shares outstanding), without the float adjustment S&P applies: the weight is indicative. Companies with two share classes count once.
Insider buying and selling in the last 30 days
From Oct 4, 2026 to Nov 3, 2026, no open-market purchases and 43 sales ($155.9M), filed on SEC Form 4 by directors, officers and 10% owners of 21 companies in the sector. Counted by trade date; grants, option exercises and transfers between the same insider's accounts are left out.
| Company | Buys | Amount | Sales | Amount |
|---|---|---|---|---|
| DVA DaVita | 0 | — | 1 | $69.0M |
| MRNA Moderna | 0 | — | 2 | $17.0M |
| ISRG Intuitive Surgical | 0 | — | 10 | $14.4M |
| CRL Charles River Laboratories International | 0 | — | 3 | $9.5M |
| DHR Danaher | 0 | — | 2 | $8.8M |
| LLY Eli Lilly | 0 | — | 1 | $7.0M |
| GILD Gilead Sciences | 0 | — | 4 | $6.3M |
| REGN Regeneron Pharmaceuticals | 0 | — | 4 | $6.2M |
| MDT Medtronic | 0 | — | 2 | $5.8M |
| ELV Elevance Health | 0 | — | 1 | $4.7M |
| TMO Thermo Fisher Scientific | 0 | — | 1 | $2.0M |
| VEEV Veeva Systems | 0 | — | 1 | $1.6M |
| RMD ResMed | 0 | — | 2 | $1.2M |
| MCK McKesson | 0 | — | 1 | $797k |
| LH Labcorp | 0 | — | 1 | $389k |
| DXCM DexCom | 0 | — | 2 | $347k |
| COR Cencora | 0 | — | 1 | $326k |
| INCY Incyte | 0 | — | 1 | $298k |
| DGX Quest Diagnostics | 0 | — | 1 | $292k |
| EW Edwards Lifesciences | 0 | — | 1 | $53k |
| BDX Becton, Dickinson | 0 | — | 1 | $15k |
Upcoming earnings dates
Dates announced by the companies themselves, from Nasdaq's public calendar (between Nov 4, 2026 and Dec 8, 2026). They are announcements, not measured dates: each company's SEC history is on its earnings page.
| Date | Company | When |
|---|---|---|
| Nov 4, 2026 | EW Edwards Lifesciences | after the close |
| Nov 4, 2026 | MCK McKesson | after the close |
| Nov 4, 2026 | STE STERIS | after the close |
| Nov 4, 2026 | TECH Bio-Techne | no time announced |
| Nov 5, 2026 | BDX Becton, Dickinson | before the open |
| Nov 5, 2026 | CAH Cardinal Health | before the open |
| Nov 5, 2026 | CI Cigna | before the open |
| Nov 5, 2026 | SOLV Solventum | after the close |
| Nov 5, 2026 | VTRS Viatris | before the open |
| Nov 5, 2026 | ZTS Zoetis | before the open |
| Nov 6, 2026 | HUM Humana | before the open |
| Nov 17, 2026 | MDT Medtronic | no time announced |
| Nov 19, 2026 | VEEV Veeva Systems | no time announced |
| Nov 23, 2026 | A Agilent Technologies | after the close |
| Dec 3, 2026 | COO Cooper Companies | no time announced |
Who reports this week across the S&P 500 →
The other S&P 500 sectors
- Basic Materials
- Communication Services
- Consumer Cyclical
- Consumer Defensive
- Energy
- Financial Services
- Industrials
- Real Estate
- Technology
- Utilities
Dividend yields in Healthcare and across the S&P 500 →
Sources: sector classification, market cap and P/E from the market-data provider (Yahoo Finance), as of the latest close downloaded; Quant500 multi-factor ranking of Nov 3, 2026; SEC Form 4 (EDGAR); Nasdaq public calendar. P/E is trailing twelve months and the median is taken per company, not per share class. Not investment advice.